On 29 July 2019, Adcock Ingram became a subsidiary of The Bidvest Group Limited, with minority shareholders owning 49% of the Company. Closer interactions are now taking place between Adcock Ingram and Bidvest, including the appointment of an additional Director to the Adcock Ingram Board of Directors to assist in exploring strategic possibilities for Adcock Ingram, to complement its range of trusted healthcare products.


The Board has declared an interim dividend of 100 cents per share for the six-month period ended 31 December 2019, out of income reserves.